ER-Positive HER2-Negative Breast Cancer
Roche’s Giredestrant Advances Oral SERD Debate at ESMO 2025
ESMO 2025; Giredestrant; Roche; Oral SERD; ER-Positive HER2-Negative Breast Cancer
Actionable Insights Powered by AI
ESMO 2025; Giredestrant; Roche; Oral SERD; ER-Positive HER2-Negative Breast Cancer